Back to top
N4 Pharma has acquired the rights to a number of new draft patent applications.

Progress to date

Progress to date

In April 2016, N4 Pharma filed 45 patent applications in the UK for the reformulation of sildenafil. This was followed in July 2016 with the filing in the UK of 17 and 12 patent applications respectively for the reformulation of losartan and valsartan, which are commonly used for treating hypertension. In December 2016, N4 Pharma filed a patent application in the UK for the reformulation of aprepitant, an anti-emetic drug used in oncology.